Skip to content
Screener

Total Equity at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$448.66M+329%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$408.73M-30.8%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
-$34.05M+44.1%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$714.56M+9.0%
Alumis Inc. logo
Alumis Inc.ALMS
$567.02M+237%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$576.22M+4,094%

Other financials

Income statement

See full
Revenue$700.0K-53.3%
Operating income-$50.6M-23.1%
Net income-$50.4M-20.3%
EPS (diluted)-$0.12+61.3%

Balance sheet

See full
Cash & equivalents$174.9M+69.5%
Total debt$7.7M+0.1%
Total assets$223.2M+55.6%

Cash flow

See full
Operating cash flow-$52.6M-55.2%
CapEx$400.0K
Free cash flow-$53.0M-56.3%

Valuation

See full
Market cap$847.16M+218%
Enterprise value$679.96M+297%
P/S168.8×+100×

Profitability

See full
Operating margin-3,543.1%+523pp
Net margin-3,506.5%+442pp
FCF margin-3,399.3%+3,268pp

Returns & leverage

See full
Return on equity-142.7%-5.0pp
Debt / equity0.0×
Current ratio3.7×+1.3×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: DBV Technologies’s 10-Q, filed July 16, 2026.

Filed
Jul 16, 2026, 4:08 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-048453
Line itemNoteJune 30, 2026December 31, 2025
Ordinary shares, €0.10 par value; 296,061,497 and 235,670,864 shares authorized, and issued as of June 30, 2026 and December 31, 2025, respectively,34.026.9
Additional paid-in capital408.3541.3
Treasury stock, 146,321 and 74,680 ordinary shares as of June 30, 2026 and December 31, 2025, respectively, at cost(0.8)(0.8)
Accumulated deficit(270.3)(393.1)
Accumulated other comprehensive income0.50.5
Accumulated currency translation effect(11.2)(5.9)
Total Shareholders’ equity160.4168.8
Total Liabilities and Shareholder's equity223.2233.7

Item 1C. Condensed Consolidated Statements of Financial Position (Unaudited) as of

FAQ

What is DBV Technologies's total equity?
DBV Technologies (DBVT) reported total equity of $160.4M in Q2 2026.
How has DBV Technologies's total equity changed year-over-year?
DBV Technologies's total equity increased by 86.1% year-over-year, from $86.2M to $160.4M.
What is the long-term trend for DBV Technologies's total equity?
Over 5 years (2020 to 2025), DBV Technologies's total equity has grown at a -3.9% compound annual growth rate (CAGR), from $205.49M to $168.8M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about DBV Technologies's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude